Conclusions Inositol supplementation may result in reduction in triglycerides , total- and LDL-cholesterol levels , but did not affect HDL-cholesterol levels  among patients with metabolic diseases .
Background Several studies have evaluated the effect of inositol supplementation on lipid profiles among population with metabolic diseases ; however , the findings are controversial .
This review of r and omized controlled trials ( RCTs ) was performed to summarize the evidence of the effects of inositol supplementation on lipid profiles among population with metabolic diseases .
Long-term effects of nutraceuticals (berberine, red yeast rice, policosanol) in elderly hypercholesterolemic patients
Introduction Statins are at the forefront of strategies to manage dyslipidemia , although they are not always well tolerated . At 6–7 months after the drug was supplied , discontinuation rates averaged 30 % . Alternate agents to statins have been studied . Some nutraceuticals demonstrated an efficacy in reducing cholesterol concentrations . However , there are no data regarding the use of nutraceuticals in elderly dyslipidemic patients . The purpose of this study was to examine the efficacy , safety , and tolerability of a nutraceutical-based protocol in elderly hypercholesterolemic patients previously intolerant to statins . Methods This study was performed as a r and omized , prospect i ve , parallel group , single-blind study . Patients were included in the study if they had high total cholesterolemia , high low-density lipoprotein cholesterol ( LDL-C ) , > 75 years of age , statin-intolerant , and were refusing other pharmaceutical treatments for hypercholesterolemia . At the baseline visit , eligible patients were r and omized to either nutraceutical-combined pill ( containing berberine 500 mg , policosanol 10 mg , red yeast rice 200 mg , folic acid 0.2 mg , coenzyme Q10 2.0 mg , and astaxanthin 0.5 mg ) or placebo , and the first dose was dispensed . The efficacy , safety , and tolerability of the proposed treatment were fully assessed after 3 , 6 , and 12 months of treatment . Results Out of 106 consecutive patients screened , 80 eligible patients were r and omized to receive either nutraceutical-combined pill ( 40 patients ) or placebo ( 40 patients ) . No patients were lost and no deaths occurred during the follow-up . There was a statistically significant reduction in total cholesterolemia ( −20 % ) , LDL-C ( −31 % ) , and insulin resistance ( −10 % ) with nutraceutical treatment . No significant changes were detected for plasma high-density lipoprotein cholesterol ( HDL-C ) . Furthermore , no statistical differences were found between baseline and end- study safety parameters . Medication compliance and tolerability were high . Conclusion In this study the authors have demonstrated that combined nutraceuticals significantly reduce cholesterolemia and achieved acceptable plasma LDL-C levels in elderly hypercholesterolemic patients who were previously statin-intolerant .  Combined nutraceuticals is also safe and well tolerated in these patients
Conclusions Inositol supplementation may result in reduction in triglycerides , total- and LDL-cholesterol levels , but did not affect HDL-cholesterol levels  among patients with metabolic diseases .
Background Several studies have evaluated the effect of inositol supplementation on lipid profiles among population with metabolic diseases ; however , the findings are controversial .
This review of r and omized controlled trials ( RCTs ) was performed to summarize the evidence of the effects of inositol supplementation on lipid profiles among population with metabolic diseases .